Announcements from the firm and its portfolio companies. We publish when there is something to say.
The California Institute for Regenerative Medicine awarded Siren Biotechnology an $8 million non-dilutive CLIN2 grant to support the Phase 1/2 trial of SRN-101 in high-grade glioma.
Title21 Health Solutions acquired cResults, adding resource planning and scheduling for QC and QA laboratory operations to its quality management portfolio.
The FDA cleared Siren Biotechnology’s first IND, enabling a first-in-human trial in adult patients with recurrent high-grade glioma and moving the company to clinical stage.
Title21 Health Solutions acquired MyCellHub and its manufacturing execution system platform, adding digital batch records and real-time production monitoring to its quality and orchestration portfolio.
The FDA granted Breakthrough Device Designation to the Avvio Enhanced Lithotripsy System for ureteral stones, giving the company priority engagement and an accelerated pathway toward a De Novo submission.
The AMA published Category III CPT code 0991T for procedures using Avvio Medical’s kidney stone treatment system, effective January 1, 2026.
KMAK Capital invests in Avvio Medical to enhance non-invasive kidney stone care, supporting patient-first, sustainable healthcare innovation.
